Pfizer Ltd.

Despite a broadly resilient market, Pfizer Ltd. has slipped to a fresh 52-week low of Rs 4,440 on 4 Jun 2026, marking a 22.54% decline over the past year and underperforming the Sensex by over 14 percentage points.

For the fifth straight session, Pfizer Ltd. closed lower, breaching its 52-week low at Rs 4,450 on 3 Jun 2026, marking a significant decline amid broader market weakness.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Pfizer Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. This change is underscored by deteriorating technical indicators including MACD, Bollinger Bands, and moving averages, signalling increased selling pressure and subdued price momentum as the stock struggles to maintain its recent levels.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 May 2026, providing investors with an up-to-date view of its performance and outlook.

Pfizer Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a recent upgrade from Hold to Sell by MarketsMOJO, the stock’s price action and technical parameters suggest a nuanced outlook for investors navigating this evolving landscape.

Pfizer Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. This change is underscored by a series of technical indicators signalling increased selling pressure, with the stock price retreating 2.59% on 14 May 2026 to close at ₹4,606.40. Investors and analysts are closely monitoring these developments as the stock navigates a challenging market environment.

Pfizer Ltd., the Indian arm of the global pharmaceutical giant, reported a net profit of ₹199.82 crores for Q4 FY26 (March 2026 quarter), marking a substantial ▲40.89% quarter-on-quarter increase from ₹141.84 crores in Q3 FY26. However, on a year-on-year basis, the performance remained subdued with a ▼39.61% decline compared to ₹330.94 crores in Q4 FY25. The stock, currently trading at ₹4,606.40 with a market capitalisation of ₹21,233 crores, has declined ▼2.59% in the latest trading session, reflecting investor concerns about the company's long-term growth trajectory and premium valuation.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 April 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.

Pfizer Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. This transition is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, which collectively suggest a cautious outlook for investors amid mixed signals.

Pfizer Ltd. is currently rated Sell by MarketsMOJO, a rating that was last updated on 29 December 2025. While this rating change occurred several months ago, the analysis and financial metrics presented here reflect the stock’s current position as of 19 April 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 April 2026, providing investors with an up-to-date view of the company's performance and outlook.

Pfizer Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish to a bearish stance. This transition is underscored by deteriorating technical indicators including MACD, Bollinger Bands, and moving averages, signalling increased selling pressure despite some bullish volume trends. Investors should carefully analyse these developments as the stock navigates a challenging market environment.

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Pfizer Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent upgrade from Hold to Sell by MarketsMOJO, the stock’s price action and technical indicators suggest a cautious outlook for investors navigating this evolving landscape.